What is Henoch‑Schönlein purpura (HSP)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

What is HSP (Henoch-Schönlein Purpura)?

Henoch-Schönlein purpura (HSP), now also called IgA vasculitis, is a systemic small vessel vasculitis characterized by IgA-mediated immune complex deposition in small blood vessels, presenting classically with palpable purpura (non-thrombocytopenic), arthralgia/arthritis, abdominal pain, and renal involvement.

Clinical Features

HSP manifests through four cardinal features 1, 2:

  • Palpable purpura: Non-thrombocytopenic purpura typically distributed on lower extremities and buttocks - this is the essential diagnostic element
  • Joint involvement: Arthralgia or arthritis (present in approximately 82% of cases) 3
  • Gastrointestinal manifestations: Abdominal pain, bowel angina, and potentially bloody diarrhea (occurs in about 54% of cases) 3
  • Renal involvement: Hematuria and/or proteinuria (affects approximately 19% of pediatric cases, though can be higher in adults) 3

Epidemiology and Demographics

HSP is predominantly a childhood disease - approximately 90% of patients are under 10 years of age with a mean age of 4 years 4. The incidence is estimated at 3-26 per 100,000 children with a male-to-female ratio of 2:1 4. The disease shows seasonal variation, being most common in fall and winter in children 4.

Pathophysiology

The disease is caused by IgA1-mediated immune complex deposition in small vessel walls, including skin capillaries and renal glomeruli 5, 6. This leads to leukocytoclastic vasculitis on histopathology. There appears to be a genetic predisposition associated with HLA class II region 4.

Diagnostic Approach

Diagnosis is primarily clinical based on the characteristic presentation, particularly the presence of palpable purpura 7. The diagnosis is strengthened by:

  • Histopathology: Leukocytoclastic vasculitis with IgA-immune deposits in vessel walls and/or glomeruli increases diagnostic sensitivity and specificity 7
  • Laboratory findings: Elevated serum IgA levels, though not always present 5
  • Urinalysis: Hematuria (present in 87.5% of affected patients) and proteinuria (75% of affected patients) when renal involvement occurs 5

Clinical Course and Prognosis

The vast majority of children with HSP have self-limited disease and do well long-term 1. In children, complete recovery occurs in 83% of patients after a median follow-up of 12 months 4. The disease is usually benign and self-limited, requiring only supportive treatment 4.

Important Timing Considerations:

  • Renal involvement typically occurs within the first month after disease onset in 68% of cases 3
  • Recurrences occur in approximately 15% of patients 3
  • Atypical presentations occur in 22% of cases, with joint involvement preceding purpura onset 3

Adult vs. Pediatric Disease

Adults with HSP have a more aggressive course compared to children 1, 5. Adults are more likely to have:

  • Severe initial renal involvement
  • Higher risk of progression to chronic kidney disease
  • Worse prognosis with proteinuria >1 g/day 1

The approach to treatment in adults should not differ from children, though the threshold for intervention may be lower given the worse prognosis 1.

Key Clinical Pitfalls

  • Do not confuse with thrombocytopenic purpura - platelet counts are normal in HSP 4, 8
  • Renal involvement can occur late - continued monitoring is essential even after initial presentation 3
  • Atypical presentations exist - joint symptoms may precede purpura in 22% of cases 3
  • Biopsy is not always necessary for diagnosis but should be performed in children with decreased renal function at presentation or severe nephrotic/nephritic syndrome 1

Related Questions

What is Henoch‑Schönlein purpura (HSP)?
Should antibiotics be prescribed for a patient with Henoch‑Schönlein purpura (IgA vasculitis) presenting with rash and vasculitis, assuming no documented bacterial infection?
Can Henoch‑Schönlein purpura recur?
How should Henoch‑Schönlein purpura be diagnosed and managed in a child presenting with a palpable purpuric rash on the buttocks and legs, arthralgia, abdominal pain, and mild hematuria?
In a 9-year-old male with right ankle swelling for 2 days, purpuric rash and petechiae on the lower legs, afebrile, stable vital signs, elevated erythrocyte sedimentation rate, and a recent nail injury to the plantar surface of the right foot, what is the appropriate management including antibiotics, imaging, and evaluation for Henoch‑Schönlein purpura?
What vancomycin dose should be administered after each thrice‑weekly hemodialysis session for a 100‑kg patient with MRSA bacteremia?
In adult ASA I‑III patients undergoing elective surgery, what intra‑operative hemodynamic parameter was used as the primary objective?
What were the outcomes of targeting a higher intra‑operative MAP (≥80 mmHg) versus the standard MAP target (≥65 mmHg) in adult ASA I‑III patients undergoing elective surgery?
What is the recommended method for switching antidepressants to minimize the risk of a switch reaction?
What is the recommended anesthetic management for major abdominal surgery, including robotic and laparoscopic procedures?
Can a person overdose on quetiapine (Seroquel) by taking an excessive amount?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.